COVID-19 : from bench to bedside / edited by Debmalya Barh, Kenneth Lundstrom.
- 其他作者：
- 其他題名：
- COVID-19 (Barh)
- 出版： Boca Raton, FL : CRC Press 2022.
- 主題： COVID-19--drug therapy. , COVID-19--diagnosis. , COVID-19--prevention & control. , Pandemics. , COVID-19 Vaccines--therapeutic use.
- ISBN： 9781032040639 (hbk.) :: GBP160.00 、 9781032040622 (pbk.)
- 書目註：Includes bibliographical references and index.
-
讀者標籤：
- 系統號： 005278538 | 機讀編目格式
館藏資訊
The COVID-19 pandemic has affected the entire world in an unprecedented way and this book provides an overview of the historical facts as well as ongoing approaches to tackle the COVID-19 pandemic. Experts of the respective domains provide details on anti-SARS-COV-2 drug strategies, including repurposing drugs used for other indications and development of novel drugs looking at different approaches to target virus entry and replication. COVID-19 vaccine development based on inactivated and attenuated live virus, protein subunit and peptide-based vaccines and utilization of vaccine candidates based on viral vectors, DNA and RNA are presented for both preclinical studies and clinical trials. Key Features - Explains the background of the COVID-19 pandemic, the current progress in the development of treatments and prevention of COVID-19 including future aspects of dealing with pandemics. - Serves as a timely repository of knowledge on COVID-19 for researchers and medical professionals engaged in its management. - Features the patent aspects of COVID-19.
摘要註
"The COVID-19 pandemic has affected the entire world in an unprecedented way and this book provides an overview of the historical facts as well as ongoing approaches to tackle the COVID-19 pandemic. Experts of the respective domains provide details on anti-SARS-COV-2 drug strategies, including repurposing drugs used for other indications and development of novel drugs looking at different approaches to target virus entry and replication. COVID-19 vaccine development based on inactivated and attenuated live virus, protein subunit and peptide-based vaccines and utilization of vaccine candidates based on viral vectors, DNA and RNA are presented for both preclinical studies and clinical trials"--